<-- Back to proposed bills
UK-US Arrangement on Pharmaceuticals Pricing and Tariffs
13 April 2026
Type
Written Ministerial Statement
Department
Department for Science, Innovation and Technology
TAGS
At a Glance
Issue Summary
The UK-US Arrangement on Pharmaceuticals Pricing and Tariffs has been published, building on previous economic prosperity deal announcements.
Action Requested
The government is taking steps to improve patient access to new medicines, clarify US pricing policies, support pharmaceutical exports with tariff-free access, and work towards mutual recognition of medical device approvals. These actions aim to enhance the life sciences sector's competitiveness and drive economic growth.
Key Facts
- The UK-US Economic Prosperity Deal was announced in May 2025.
- NICE cost effectiveness threshold update benefits two medicines for brain cancer and rare stomach cancer patients.
- Section 232 tariffs of up to 100% on patented pharmaceuticals have been avoided, providing certainty for UK exporters.
- UK pharmaceutical exports to the US were worth over £5 billion in 2024.
- The UK pharmaceutical sector added £28.5bn to the economy and employed over 50,000 people in 2025.
- Section 232 and Section 301 tariffs will not be imposed on medical technology exports for at least three years.
- UCB announced a £500 million investment in UK R&D and manufacturing in Surrey.
▸
Assessment & feedback
Summary accuracy